Some key prescription drugs for which Johnson & Johnson expects to seek approval by 2015:
_Bapineuzumab, injection to slow progress of Alzheimer's disease.
_Canagliflozin, for Type 2 diabetes.
_Sirukumab, injection for rheumatoid arthritis.
_Fulranumab, injection for pain caused by osteoarthritis or nerve problems.
_TMC 207, or multi-drug-resistant tuberculosis.
_TMC 435, for hepatitis C.
_FlumAb, injection for respiratory infections.
_FluCell, influenza vaccine.